http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2396704-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e56c0ba1380fdfedb47ab5378a972a72 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235 |
| filingDate | 2001-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08e2ca7157d9532c15e252be7cd0f867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9511f02066676878a072dcdc2952eb1a |
| publicationDate | 2001-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2396704-A1 |
| titleOfInvention | Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents |
| abstract | Hypericin, helianthrone and derivatives thereof of general formula (I) where in the dotted line between positions 11 and 12 represents an optional C11-C12 bond; R is selected from the group consisting of hydroxy, C1-C10 alkoxy, NH- C1- C10 alkyl, and NH-hydroxy(C1-C10)alkyl but R is H at positions 8 and 15 when there is no C11-C12 bond; R' is selected from the group consisting of hydrox y and C1-C10 alkoxy; and R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxy, chloro, bromo, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 alkoxycarbonyl, are useful as inhibitors of angiogenesis and can be used to prevent formation of metastases and restenos is and for the treatment of angiogenesis-associated ophthalmologic disorders. I n addition, the helianthrones of formula (I) can be used for the treatment of tumors in the absence of light irradiation. |
| priorityDate | 2000-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 144.